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Abstract
Background: Improved walking is one of the highest priorities in people living with stroke. Post-stroke lower limb
spasticity (PSLLS) impedes walking and quality of life (QOL). The understanding of the evidence of improved walking
and QOL following botulinum toxin (BoNTA) injection is not clear. We performed a systematic review of the
randomized control trials (RCT) to evaluate the effectiveness of BoNTA injection on walking and QOL in PSLLS.
Methods: We searched PubMed, Web of Science, Embase, CINAHL, ProQuest Thesis and Dissertation checks,
Google Scholar, WHO International Clinical Trial Registry Platform, ClinicalTrials.gov, Cochrane, and ANZ and EU
Clinical Trials Register for RCTs looking at improvement in walking and QOL following injection of BoNTA in
PSLLS. The original search was carried out prior to 16 September 2015. We conducted an additional verifying
search on CINHAL, EMBASE, and MEDLINE (via PubMed) from 16 September 2015 to 6 June 2017 using the same
clauses as the previous search. Methodological quality of the individual studies was critically appraised using
Joanna Briggs Institute’s instrument. Only placebo-controlled RCTs looking at improvement in walking and QOL
were included in the review.
Results: Of 2026 records, we found 107 full-text records. Amongst them, we found five RCTs qualifying our
criteria. No new trials were found from the verifying search. Two independent reviewers assessed methodological
validity prior to inclusion in the review using Joanna Briggs Institute’s appraisal instrument. Two studies reported
significant improvement in gait velocity (p = 0.020) and < 0.05, respectively. One study showed significant improvement
in 2-min-walking distance (p < 0.05). QOL was recorded in one study without any significant improvement. Meta-analysis
of reviewed studies could not be performed because of different methods of assessing walking ability, small sample size
with large confidence interval and issues such as lack of power calculations in some studies. Findings from our
systematic and detailed study identify the need for a well-designed RCT to adequately investigate the issues highlighted.
Conclusions: This review could not conclude there was sufficient evidence to support or refute improvement on
walking or QOL following BoNTA injection. Reasons for this are discussed, and methods for future RCTs are developed.
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Background
Stroke is a common cause of adult disability worldwide
[1]. More than two thirds of the stroke survivors develop
post-stroke sequelae including impaired motor functions
and spasticity [2]. The prevalence of post-stroke spasti-
city ranges from 19.0 to 42.6% [3]. There have been
many recent developments in diagnosis, management,
and prevention of stroke, while advances in rehabilita-
tion have been modest [4]. There has, however, been
progress with the use of botulinum toxin (BoNTA) as a
treatment to improve spasticity in the upper limb [5–7].
Three systematic reviews [8–10] have addressed research
progress on both the upper and lower limbs, with the
conclusion from two of these that the effect on the
upper and lower limbs spasticity favored BoNTA [8, 9];
however, these reviews did not fulfill the criteria for in-
clusion in this study.
As far as the lower limb is concerned, improvement in
spasticity while important is only a first stage in post-
stroke improvement, and the aim of RCTs should be to
address the more important questions of functional ac-
tivity including walking. How well this outcome has
been addressed is the aim of this study. This is also an
important question for many countries to resolve, be-
cause to date, botulinum toxin A is not approved for use
in the post-stroke lower limb spasticity (PSLLS) by the
pharmaceutical authorities except in the USA [11].
Lower limb spasticity most commonly involves the
foot and the ankle leading to equinovarus (plantarflexion
and inversion) deformity. Post-stroke patients with equi-
novarus deformity fail to achieve optimal contact with
the ground leading to a poor stance, loss of heel to toe
rhythm while walking and post-stroke patients walk pre-
dominantly with plantarflexion/inversion of the foot.
Transfers and walking are essentially bipedal activity in-
volving phases like balancing on one leg and swinging
the other leg forward. The awkward position of the foot
in addition to spasticity impairs balance, transfer, stride,
gait, and mobility, besides causing spasm and pain. In
many cases, complications like falls, fractures, deep vein
thrombosis, and pressure ulcers may also result [12]. In-
ability to walk is associated with loss of independence
and premature residential aged care placement [13, 14]
and in the older population contributes substantially to
adverse health outcomes including activities of daily living
and mortality [15]. Improving and maintaining walking
ability and activities of daily living are therefore vital for
post-stroke survivors [16] and a major contributor to
functional improvements. The overall human and eco-
nomic cost of spasticity is, therefore, considerable, and in-
terventions potentially can deliver significant benefits [17].
Given the evidence for efficacy of BoNTA in reducing
spasticity, the objective of this review was to assess the
available evidence of BoNTA injection: (1) to improve
mobility (using gait velocity and walking distance as
measuring parameters) and quality of life (QOL) and (2)
to make appropriate recommendations for further re-
search regarding these questions.
Methods
Review searches
The protocol used for this systematic review has been
previously published [18]. In review searches, this review
considered components of the protocol included in the
literature search strategy of the studies, screening cri-
teria and data extraction methods, assessment of meth-
odological quality, and data collection and synthesis of
data. Briefly, the literature search was performed on
PubMed, Web of Science, EMBASE, CINAHL, ProQuest
Thesis and Dissertation checks, and Google Scholar to
identify RCTs prior to 16 September 2015. Medical sub-
ject headings and their indexing counterparts including
“botulinum toxin,” “stroke,” and “muscle spasticity” were
combined to search these databases, with filter settings
for humans and English language activated. Detailed de-
scription of the search strategies for PubMed and Web
of Science is provided in Table 1. Bibliographic reference
lists of systematic reviews, which were dentified during
screening, were searched to locate any studies that were
not identified through the electronic literature database
searches. To ensure unpublished RCTs missed through
this process were not excluded, WHO International Clin-
ical Trial Registry Platform (WHO-ICTRP), ClinicalTrials.-
gov, Cochrane Clinical Trial Register (CCTR), Australian
New Zealand Clinical Trials Registry (ANZCTR), and EU
Clinical Trials Register (EUCTR) were also searched using
the same combination of keywords.
Inclusion and exclusion criteria
The authors screened independently the title and ab-
stract of studies, identified through the literature for po-
tential inclusion. For this study, BoNTA (Botox® or
Dysport® or Xeomin®) was defined to include any clinical
use, of any dosage or duration, for the treatment of adult
post-stroke lower limb spasticity (PSLLS). The review in-
cludes RCTs examining the use of BoNTA versus pla-
cebo use in adult PSLLS and included spasticity of any
lower limb muscle of any severity or duration. The func-
tional outcomes included were gait velocity, walking dis-
tance, and QOL measures.
The review excluded studies without a placebo-control
group, observational studies using other types of
BoNTA, or studies not reporting any of the outcomes
mentioned above. Studies involving spasticity of non-
stroke etiology, immobile patients, and patients with
fixed contracture or pregnancy were also excluded.
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Data extraction
Two reviewers (ADG and WHC) independently ex-
tracted data from the included studies. Data included
sample size, study design, intervention methodology,
participant randomization, timing of intervention and
follow up, and outcomes—including gait speed, walking
distance, and/or QOL. Other functional outcomes of sig-
nificance were also extracted.
Assessment of methodological quality
Methodological quality of the studies was not addressed
until the final selection of studies had been made for this
systematic review. Methodological quality of individual
studies was critically appraised using Joanna Briggs Insti-
tute’s instrument and included in our study analysis.
Those with RCT scores ≥ 8 were included in the study
(Table 2). This instrument mandates that the quantita-
tive papers are selected for retrieval by two independent
reviewers for methodological validity prior to inclusion
in the review using standardized critical appraisal from
the institute’s review instrument [19].
Results
Description of the included studies
No studies included in this review were excluded based
on their quality scoring. Table 2 shows that accepted
studies achieved a quality score of at least 8. Below this
score, studies were excluded because they were not
RCTs or did not include a placebo control.
Figure 1 illustrates the PRISMA diagram with all the
RCTs and the flow chart for the reviewing process. We
identified 2112 records through database searches and
406 records from other sources. After removing the re-
dundant studies, we ended with 2026 records. On
screening for title and abstracts, we found 107 full-text
records. Amongst them, the number of non-RCT and
quasi-RCTs was 102 and thus leaving five studies for fur-
ther analysis. Table 2 summarizes the total scores of the
five RCTs, which qualified for further analysis based on
the quality assessment according to the predetermined
criteria. Table 3 compares the main features including
design, sample size, age group; exclusion criteria, power
calculation, intervention, study results, and primary out-
come measures that met the inclusion criteria.
Quality of the included studies
Table 3 shows that each of the studies had a different
primary outcome measure [20–24]. Variation between
studies also extended to age group, inclusion criteria,
and intervention protocol. Despite this, it can be seen
from Table 3 that there were many promising outcomes.
Tao et al. [20] showed gait analysis (step length, cadence,
and speed) improved in the treatment group, and
Johnson et al. [21] demonstrated treatment group
changes in the effort of walking (speed walkway) and im-
provement in mobility. There were also improvements
in spasticity (MAS) in all studies, though in the Johnson
study, this may not be related to the intervention.
Johnson et al. [21] also reported a non-significant im-
provement in the self-reported quality of life (SF-36).
Despite the overall significant outcomes in various func-
tional measures, there was little corroboration of im-
provement in functional outcomes across studies, and it
was concluded that, given the range of variations in
study measures between studies, a meta-analysis of the
data should not be conducted. The decision is supported
by the different inclusion criteria (e.g., age, ambulatory
status, homogeneity) used in each study, which raises
the question of sample comparability. Furthermore, al-
though spasticity is clearly and successfully measured as
Table 1 PubMed and Web of Science search strategies
PubMed
Search number Search terms
1 Botulinum toxins[MeSH] OR Botulinum toxin*[tw]
OR Botulin[tw] OR Clostridium botulinum toxin*
[tw] OR Botulinum toxin type A[tw] OR “Clostridium
botulinum A”[tw] OR “Clostridium botulinum type A”
[tw]
2 Stroke[MeSH] OR Stroke[tw] OR strokes[tw] OR
Apoplexy[tw] OR CVA[tw] OR CVAs[tw]
OR “Cerebrovascular Accident”[tw] OR
“Cerebrovascular Accidents”[tw] OR “Cerebrovascular
Apoplexy”[tw]
OR “Cerebrovascular Stroke”[tw] OR “Cerebrovascular
Strokes”[tw] OR “Brain Vascular Accident”[tw]
OR “Brain Vascular Accidents”[tw] OR “Cerebral Stroke
”[tw] OR “Cerebral Strokes”[tw] OR “Acute Stroke”[tw]
OR “Acute Strokes”[tw]
OR “Acute Cerebrovascular Accident”[tw]
OR “Acute Cerebrovascular Accidents”[tw]
3 Muscle Spasticity[MeSH] OR Spasticity[tw] OR
Spastic[tw] OR Hypertonia[tw] OR “muscle
overactivity”[tw]
4 #1 AND #2 AND #3
5 Filters - Species: Humans; Languages: English; Search
Date: 16/9/2015
Web of Science Search terms
1 Botulinum toxin or Botulin or Clostridium botulinum
toxin or Botulinum toxin type A
or Clostridium botulinum A
or Clostridium botulinum type A
2 Stroke or Apoplexy or CVA or Cerebrovascular
Accident
or Cerebrovascular Apoplexy or
Cerebrovascular Stroke or Brain Vascular Accident
or Cerebral Stroke or Acute Stroke or Acute
Cerebrovascular Accident
3 Spasticity or Spastic or Hypertonia or Muscle
overactivity
4 #1 AND #2 AND #3
5 Filters - Species: Humans; Languages: English;
Search Date: 16/9/2015
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an outcome in all studies, the methods used to assess
walking ability varied between studies, and no more than
two studies used the same methods with successful
outcomes. This would not support a substantial meta-
analysis, and in addition, further design issues were appar-
ent. The potential for meta-analysis was also invariably
compromised in studies assessing the same outcome, i.e.,
gait speed and MAS, because of small sample size and
large confidence intervals around the estimate. In
addition, where estimates for outcomes were positive,
three studies did not report power calculations [20, 21].
As shown in Table 3, the absence of a power calculation
in three of the studies is a serious design shortcoming.
Kaji et al. [22] and Pittock et al. [23] were the only investi-
gators to provide a power calculation. The largest study
sample, which did include a power calculation, exceeded
the smallest sample size by a factor of 10 [23]; this ser-
iously questions the sample size calculations used in the
smaller studies and therefore the reliability of estimates.
For the remaining studies, it should be reinforced that a
small sample size in studies reduces the chance of detect-
ing a true effect but, in addition, low power (which is a
characteristic of the smaller studies) also increases the
chance of both type 1 and type 2 errors. Given the age
ranges of the smaller study samples included in the
present study, assumptions of study representativeness are
seriously questioned, and consequently, if the distribution
of the study sample is skewed, the t test (used in the
smaller studies) is not appropriate. Reliability is also ques-
tioned in the Kaji et el. study [22], which was of short dur-
ation of only 12 weeks following long post-stroke period
of 6 years. In addition, none of the studies used other im-
portant indices to assess functional outcomes such as bal-
ance (Berg Balance Score); Timed Up and Go (TUG), a
test for mobility; or the Goal Attainment Scale (GAS), a
patient perceived assessment of improvement in function.
Fig. 1 PRISMA flow diagram
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Underpinning assessment of the quality of all these
studies is the issue of repeated measures and assessment
of temporal trends. The assessment of temporal trends
was poorly handled. For the most part, change over time
was assessed by comparing separately each time point to
baseline (e.g., Pittock et al. [23]; week 4 to baseline, week
8 to baseline, and week 12 to baseline), and this ap-
proach suffers two limitations: first, time trends are not
well characterized as this would require all time points
to be assessed simultaneously; second, the approach fails
to acknowledge that the outcome at one time in point
may be influenced by earlier assessments. It is a known
feature of repeated measures data that outcomes within
patients are correlated, and the failure to account for
this in the analysis has serious consequences. Variance
estimates are likely to be biased (variance is underesti-
mated) which increases the risk of reporting a type 1
error. Two studies applied alternative methods to
characterize trends over time. Johnson et al. [21] used
simple linear regression, although it is not clear how this
was applied. Since these authors argued that mean dif-
ferences across time points could not be directly com-
pared, it would seem reasonable to assume that they
entered each time point as separate covariates. Their so-
lution to resolving these issues with the comparisons
was to run an ANCOVA hence producing baseline ad-
justed effects for the final assessments. The use of sim-
ple linear regression and/or ANCOVA is inappropriate
in this instance; observations are treated as independent
(i.e., uncorrelated) observations resulting, again, in vari-
ance being underestimated with the consequential in-
creased risk of reporting a type 1 error. Kaji et al. [22]
attempted to characterize group differences in temporal
trends for the primary outcome by analyzing area under
the curve (AUC). It is not clear why this approach was
taken as AUC is generally used for other purposes, for
example, in pharmacology, to plot concentrations of
drugs in blood plasma over time [25]. It is difficult to re-
late this to the purpose of the trial, which is to assess
the efficacy and safety of the treatment, which, we con-
clude, is best assessed using other methods.
Discussion
This review shows the evidence for functional improve-
ment such as walking and QOL using BoNTA for PSLLS
to be inconclusive, given the variations and shortcom-
ings in study designs and methodologies. Thus, we argue
meta-analysis should not be undertaken to assess the ef-
ficacy of BoNTA on functional outcomes. We would,
however, conclude that the studies do provide some
promising indications of improvement in functional out-
comes that requires re-investigation in a well-planned
RCT with substantial design and analytic changes. About
design, appropriate sample calculations must be based
on a repeated measures design. The optimum approach
to analyze repeated measures data in future RCTs would
be to apply repeated measures ANOVA or a linear
mixed-effects model, unlike simple linear regression and
ANCOVA as applied by Johnson et al. [20]. With these
methodological changes, direct comparisons between
groups and between time points can be made. They also
account for patient correlations with appropriate adjust-
ments to variance estimates hence reducing the risk of
reporting a type 1 error. As already mentioned, power
calculations were not reported in three studies, and
given the small sample assessed, this is likely to be a sig-
nificant limitation. Kaji et al. [22] did report power cal-
culations and obtained a sample larger than the one
required. However, the effect size reported was lower
than that assumed for the calculations (3.428 vs. 5.0)
with the consequent loss of statistical power. This
slipped from 90 to 80% even with the addition of
approximately 11 subjects per group. While 80% power
is the standard for most studies, more power is often
used in clinical trials and should be used in future RCTs.
Pittock et al. [23] provided power calculations and re-
cruited a sample that was larger than indicated by the
calculations. However, the obtained effect size was not
reported for the parameter that was used as the basis for
the power calculation, and it is difficult to establish
whether the requisite power was obtained although this
was likely. Sample sizes need also to take account of
stratification in the study analyses. Furthermore, BT in-
jection is a focal injection, and the effect size from such
injection is likely to be small, and hence, the optimal
sample size needs to be calculated using minimum clin-
ically important difference (MCID) in the primary out-
come with adequate power.
Future RCTs should include homogenous post-stroke
patients with similar baseline characteristics, intact cog-
nition, and with some walking ability. It is unlikely that
patients with significant PSLLS who are unable to move
will achieve active functions such as walking post-
BoNTA injection. Other studies need to be designed to
consider improvements for these more severe post-
stroke patients. Significant receptive aphasia impedes
participation in rehabilitation, and these patients should
be excluded. Best outcomes may be achieved if BoNTA
is administered as early as two-week post-stroke [26].
Future studies should also consider gait velocity or 6-
min walk test as primary outcomes as per International
Classification of Functions (ICF) [27]. Only two studies in
our review included this clearly. It is also necessary to
document activity limitation and participation restriction
according to the International Classification of Function-
ing, Disability and Health [27]. Oher functional outcomes
should be considered for inclusion including balance (by
Berg Balance Score), Time Up and Go (TUG), and the
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Goal Attainment Scale (GAS). Minimization of PSLLS
may facilitate recovery of balance [28]. Studies should also
consider economic analyses for cost-benefit purposes such
as quality-adjusted life years (QALYs) from the quality of
life measures. QALYs are measures of disease burden
which includes both quality and quantity of life lived and
a value of health outcome.
Accuracy of the intervention using BoNTA is also
dependent on the use of injection guidance such as elec-
tromyograph (EMG) or ultrasound (US). In this review,
only three studies did so. The involved muscles should
be identified through functional activities such as walk-
ing where possible and confirmed by EMG or US prior
to proceeding with injection for optimum result. It is
important to understand that the equinus component of
the equinovarus deformity is caused by the spastic
gastrocnemius/soleus with contributions from the tibi-
alis posterior and other long toe flexors, whereas a varus
deformity is mostly caused by the tibialis posterior. It is
important to identify and inject the specific muscles
causing the deformity. Pittock et al. [23] failed to do this.
BoNTA works in conjunction with other conventional
therapies like physiotherapy and splinting. Once BoNTA
has reduced the spasticity, patients need gait training to
learn new motor control facilitating the speed of walking
and walking distance. Evidence suggests that intensive
repetitive practice with incremental difficulty within the
tolerance limit can enhance walking ability [29]. A stan-
dardized physical therapy should be designed to address
intensity, frequency, and duration in future RCTs.
Three other systematic reviews deserve mentioning
before concluding. The first of these by Foley et al. [30]
reviewed the effects of BoNTA on gait velocity on five
RCTs and three uncontrolled studies using small sam-
ples and found a small improvement in gait velocity.
Two of these studies were included in our review. The
second by Baker et al. [31] assessed BoNTA effects on
gait speed and quality of life and found no significant ef-
fect using two of the studies included in this review.
More importantly, this review was not stroke specific.
Most recently, Wu et al. [32] used seven studies to as-
sess lower limb spasticity only. The present review in-
cluded four of the studies included by Wu et al. This
review included studies on lower limb spasticity of het-
erogeneous origin, and some studies were not placebo-
controlled RCTs [32].
Limitations
The search was over 1 year old during preparation and
submission. We conducted an additional verifying search
on CINHAL, EMBASE, and MEDLINE (via PubMed)
from 16 September 2015 to 6 June 2017 using the same
clauses as the previous search, and no relevant trial was
identified.
The review was limited by the inability to conduct
meta-analysis of the data. We employed very strict cri-
teria in the selection of the included RCTs and excluded
many uncontrolled studies. Significant heterogeneity of
outcomes limited the ability to draw firm conclusions,
and we were unable to test publication bias.
Conclusions
In conclusion, this systematic review has demonstrated
the need for further research into the use of BoNTA for
PSLLS. There is a significant lack of well-designed RCTs
assessing functional improvement in PSLLS post-
BoNTA injection. It is important therefore to invest in a
well-designed BoNTA study to investigate more thor-
oughly the effects on active functioning such as walking
and functional ability in PSLLS. The compound has
already demonstrated the ability to reduce spasticity, but
to argue, BoNTA is a standard treatment for PSLLS, its
effects on walking and functional ability must be estab-
lished. It is highly recommended that study initiatives
should be directed toward achieving functional out-
comes and participation goals [33]. We propose an ad-
equately powered placebo-controlled study of BoNTA
on a homogenous group of patients with PSLLS who
have some walking ability. The study should have the
sample size calculated from the MCID of the primary
functional outcome of gait velocity or other important
functional outcomes including QOL, which may require
larger sample size than used in studies to date. Appro-
priate muscle selection and targeted injection, standard-
ized adjuvant therapy, and proper statistical methods are
essential in finding the benefits on the lower-limb func-
tions. Finally, we return to the purpose of using BoNTA
for lower limb functionality. If the aim of such studies is
only to reduce spasticity, this is already proven, the real
challenge is improving function and quality of life. This
review has informed us to design our own RCT (cur-
rently underway) in our hospital looking at the improve-
ment of lower limb functioning such as walking and
quality of life in post-stroke lower limb spasticity using
botulinum toxin [34].
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